DIAGNOSTICS INTELLIGENCE
Track the tests, biomarkers, workflows and evidence needed to move salivary diagnostics from interesting science into clinical infrastructure.
THE QUESTION
A diagnostic can be scientifically interesting without being clinically useful. Oral Signal evaluates whether a test or technology reliably measures a signal, whether that signal predicts something that matters, whether it changes a decision, and whether the workflow and economics support adoption.
Track the tests, biomarkers, workflows and evidence needed to move salivary diagnostics from interesting science into clinical infrastructure. Oral Signal treats this as a living intelligence topic rather than a one-time article. The page is designed to connect the underlying evidence with the companies, payer activity, infrastructure and implementation questions that determine whether the signal becomes useful in real healthcare.
The strongest source-backed signals we are using to evaluate this topic. Each finding is paired with the narrower interpretation Oral Signal believes the evidence supports.
ORAL SIGNAL READ
Saliva has credible diagnostic signal, but validation and standardization remain gating issues for broad deployment.
ORAL SIGNAL READ
A single point-of-care biomarker may be useful as a screening signal, but these performance characteristics do not support treating it as a replacement for comprehensive clinical diagnosis.
We look for primary evidence, documented programs and observable market activity that clarify this dimension of salivary diagnostics. New evidence should strengthen, weaken or qualify the current view rather than simply add another headline.
We look for primary evidence, documented programs and observable market activity that clarify this dimension of salivary diagnostics. New evidence should strengthen, weaken or qualify the current view rather than simply add another headline.
We look for primary evidence, documented programs and observable market activity that clarify this dimension of salivary diagnostics. New evidence should strengthen, weaken or qualify the current view rather than simply add another headline.
We look for primary evidence, documented programs and observable market activity that clarify this dimension of salivary diagnostics. New evidence should strengthen, weaken or qualify the current view rather than simply add another headline.
We look for primary evidence, documented programs and observable market activity that clarify this dimension of salivary diagnostics. New evidence should strengthen, weaken or qualify the current view rather than simply add another headline.
WHY IT MATTERS
The most valuable diagnostic is not necessarily the most novel biomarker. It is the one that creates reliable information at the right point in a workflow and leads to an action worth taking.
For healthcare leaders, the practical questions are who should act, at what point in the workflow, using what evidence, and who captures enough value to pay for the intervention. Those questions are especially important in oral-systemic health because dental benefits, medical benefits, provider systems and clinical data often sit in separate operating structures.
HOW TO READ THE EVIDENCE
Oral Signal separates four layers: association, mechanism, intervention and economics. Association asks whether two conditions occur together more often than expected. Mechanism asks whether a credible biological pathway could connect them. Intervention evidence asks whether changing oral health changes a meaningful downstream outcome. Economics asks whether any demonstrated benefit is large and reliable enough to support a scalable program.
That hierarchy matters. A topic can be clinically important even when the highest level of evidence is incomplete. In those cases, screening, referral, data sharing or further study may be justified while stronger treatment or savings claims remain premature.
ORAL SIGNAL STANDARD
Every topic is connected back to underlying evidence, market signals or program analysis. We distinguish reported associations from causal claims, announced programs from measured outcomes, and commercial availability from demonstrated clinical utility. As the evidence changes, these hubs are intended to become durable reference points rather than one-time news posts.